Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enclomifene - Repros Therapeutics

Drug Profile

Enclomifene - Repros Therapeutics

Alternative Names: Androxal; Enclomid; Enclomifene citrate; Enclomiphene; Enclomiphene citrate; trans-clomifene; Trans-clomiphene; Trans-clomiphene-citrate

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Repros Therapeutics
  • Class Antineoplastics; Diethylamines; Ethanolamines; Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Hypogonadism
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 13 Mar 2019 Enclomifene is still in pre-registration for Hypogonadism1 in European Union
  • 13 Mar 2019 No development reported - Preregistration for Hypogonadism in USA (PO)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top